Patient-Reported Adverse Events during Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)
- Citation:
- Ann Surg vol 278 (4) 598-608
- Year:
- 2023
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- Yes
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 13
- Parents:
- 3911
- Children:
- None
- Program:
- OGC
- Primary Committee:
- GI
- Sec. Committees:
- Health Outcomes
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, UG1CA189823, UG1CA189850, UG1CA232760, UG1CA233290, UG1CA233329, U10CA180868(NRG); P30 CA008748
- Corr. Author:
- Authors:
- Rebecca A. Snyder Amylou C. Dueck Briant Fruth Qian Shi Joleen M. Hubbard Joseph M. Herman Eileen M. O'Reilly Matthew H.G. Katz
- Networks:
- LAPS-MN026, LAPS-NY016, LAPS-TX035, METROMIN, NORTHWELL
- Study
- Alliance-A021501
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Article